S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
Log in

Biotron Limited (BIT.AX) Stock Forecast, Price & News

Today's Range N/A
50-Day Range
MA: A$0.09
52-Week Range N/A
Volume1.03 million shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
Biotron Limited, a biotechnology company, engages in the developing and commercializing small molecule products to treat various viral diseases in Australia. Its lead antiviral drug is BIT225, which is in Phase II clinical trials for the treatment of HIV-1 and hepatitis C virus infections. The company also develops a portfolio of preclinical antiviral drugs. Biotron Limited was incorporated in 1999 and is based in North Ryde, Australia.


Overall MarketRank

0.54 out of 5 stars

Analyst Opinion: 0.0Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Biotechnology
Phone61 2 9805 0488



Sales & Book Value

Annual Sales$803,026.00
Book ValueA$0.01 per share



Next Earnings DateN/A
OptionableNot Optionable

Receive BIT News and Ratings via Email

Sign-up to receive the latest news and ratings for BIT and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Biotron Limited (BIT.AX) (ASX:BIT) Frequently Asked Questions

What stocks does MarketBeat like better than Biotron Limited (BIT.AX)?

Wall Street analysts have given Biotron Limited (BIT.AX) a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Biotron Limited (BIT.AX) wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Who are some of Biotron Limited (BIT.AX)'s key competitors?

What other stocks do shareholders of Biotron Limited (BIT.AX) own?

Who are Biotron Limited (BIT.AX)'s key executives?

Biotron Limited (BIT.AX)'s management team includes the following people:
  • Dr. Michelle Miller BSc., GCertAppFin, Ph.D., MSc., CEO, MD & Exec. Director
  • Mr. Peter James Nightingale B.Econ, CA, Company Sec. (Age 64, Pay $84k)
  • Dr. Stephen L. Becker M.D., Chief Medical Officer

What is Biotron Limited (BIT.AX)'s stock symbol?

Biotron Limited (BIT.AX) trades on the ASX under the ticker symbol "BIT."

How big of a company is Biotron Limited (BIT.AX)?

Biotron Limited (BIT.AX) has a market capitalization of $0.00 and generates $803,026.00 in revenue each year. Biotron Limited (BIT.AX) employs 3 workers across the globe.

What is Biotron Limited (BIT.AX)'s official website?

The official website for Biotron Limited (BIT.AX) is www.biotron.com.au.

How can I contact Biotron Limited (BIT.AX)?

The company can be reached via phone at 61 2 9805 0488.

This page was last updated on 1/24/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.